Evidence map›Paper›PMID 39963469›Full record

ReviewRSC advances2025

Exploring the frontiers of emerging sensing of silver nanoprisms: recent progress and challenges.

Houman Kholafazad Kordasht, Parinaz Bahavarnia, Farnaz Bahavarnia, Mohammad Hasanzadeh, Nasrin Shadjou

Abstract readReview
In one paragraph

Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Houman Kholafazad KordashtNutrition Research Center, Tabriz University of Medical Sciences Tabriz Iran.ORCID https://orcid.org/0000-0002-7919-9272
Parinaz BahavarniaFood and Drug Safety Research Center, Tabriz University of Medical Sciences Tabriz Iran.
Farnaz BahavarniaAsian Nano Ink (ANI) Company Tabriz Iran.
Mohammad HasanzadehPharmaceutical Analysis Research Center, Tabriz University of Medical Sciences Tabriz Iran hasanzadehm@tbzmed.ac.ir.ORCID https://orcid.org/0000-0003-4918-1239
Nasrin ShadjouDepartment of Nanotechnology, Faculty of Chemistry, Urmia University Urmia Iran.ORCID https://orcid.org/0000-0001-5961-3686

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the development and use of nanomaterials have transformed numerous aspects of biomedical science. Nanomaterials have played a pivotal role in advancing disease diagnosis and treatment across a wide range of applications. Within this scope, silver nanoprisms (AgNPrs) stand out due to their remarkable properties, such as extensive surface area, chemical robustness, and tunable electrical conductivity, making them excellent candidates for biomedical purposes. By tailoring these nanomaterials through functionalization or coating surface, their multifunctionality can be enhanced, unlocking new opportunities for their application in areas such as diagnosis, imaging, and therapeutic intervention. This review begins with an overview of AgNPrs' synthesis techniques and their unique physicochemical characteristics. Recent advancements in analytical methods utilizing AgNPrs, categorized by sensing mechanisms such as optical and electrochemical approaches, are highlighted in the context of diagnostics. Lastly, the challenges and future prospects of bringing AgNPr-based technologies to commercialization and integrating them into disease diagnostics and medical treatment are explored. The integration of AgNPrs in disease therapy holds promise for the development of advanced chemotherapy agents that effectively address the challenges of efficient cancer treatment looking ahead, the ongoing advancement of nanocarrier systems comprising AgNPrs-based molecules holds great promise for improving the quality of life for patients worldwide.

Identifiers

PMID39963469
PMCPMC11831252

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.